Your browser doesn't support javascript.
loading
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen, Julia; Vredevoogd, David W; Krijgsman, Oscar; Ligtenberg, Maarten A; Blankenstein, Stephanie; de Bruijn, Beaunelle; Frederick, Dennie T; Kenski, Juliana C N; Parren, Mara; Brüggemann, Marieke; Madu, Max F; Rozeman, Elisa A; Song, Ji-Ying; Horlings, Hugo M; Blank, Christian U; van Akkooi, Alexander C J; Flaherty, Keith T; Boland, Genevieve M; Peeper, Daniel S.
Afiliación
  • Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Blankenstein S; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Frederick DT; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Kenski JCN; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Parren M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Brüggemann M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Madu MF; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rozeman EA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Song JY; Division of Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Horlings HM; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Blank CU; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Akkooi ACJ; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Flaherty KT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. d.peeper@nki.nl.
Nat Commun ; 14(1): 672, 2023 Feb 07.
Article en En | MEDLINE | ID: mdl-36750559
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos